



OPEN ACCESS

EDITED AND REVIEWED BY
Graça Soveral,
University of Lisbon, Portugal

*CORRESPONDENCE
Alan M. Jones,
✉ a.m.jones.2@bham.ac.uk

RECEIVED 30 September 2024
ACCEPTED 25 November 2024
PUBLISHED 19 December 2024

CITATION
Alshehri JA, Gill DM and Jones AM (2024)
Corrigendum: A sulfuryl group transfer
strategy to selectively prepare sulfated
steroids and isotopically labelled derivatives.
Front. Mol. Biosci. 11:1504226.
doi: 10.3389/fmolb.2024.1504226

COPYRIGHT
© 2024 Alshehri, Gill and Jones. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: A sulfuryl group transfer strategy to selectively prepare sulfated steroids and isotopically labelled derivatives

Jaber A. Alshehri, Daniel M. Gill and Alan M. Jones*

Molecular Synthesis Laboratory, School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, United Kingdom

KEYWORDS

sulfation, selectivity, isotopic labelling, sulfuryl transfer, TBSAB

A Corrigendum on

A sulfuryl group transfer strategy to selectively prepare sulfated steroids and isotopically labelled derivatives

by Alshehri JA, Gill DM and Jones AM (2021). *Front. Mol. Biosci.* 8:776900. doi: 10.3389/fmolb.2021.776900

In the published article, there was an error in [Scheme 2](#) as published. The stereogenic center in compounds 9-11 was incorrectly depicted. The corrected [Scheme 2](#) and its caption appear below.

In the published article, there was an error in [Supplementary Data Sheet 1](#), section Compound characterisation. The name of the fourth compound was incorrectly captured as “Pregnanediol or (3S,8S,9S,10R,13S,14S,17S)-17-((S)-1-hydroxyethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (9).”

The correct name appears below:


“Pregnanediol or (3S,8S,9S,10R,13S,14S,17S)-17-((R)-1-hydroxyethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (9).”

In the published article, there was an error in [Supplementary Data Sheet 1](#), section Compound characterisation. The name of the fifth compound was incorrectly captured as “Disodium-3,17-pregnanediol disulfate or sodium (S)-1-((3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-(sulfonatoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl sulfate (11).”

The correct name appears below:

“Disodium-3,17-pregnanediol disulfate or sodium (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((R)-1-(sulfonatoxy)ethyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl sulfate (11).”

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.



Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.